Literature DB >> 26331518

Subsequent pregnancies in women with previous gestational syphilis.

Marjorie Garlow Hebmuller1, Humberto Holmer Fiori1, Eleonor Gastal Lago1.   

Abstract

This study included data on syphilis-positive pregnant women seen for delivery or miscarriage, between 1997 and 2004, in Sao Lucas Hospital, Porto Alegre, RS. Their subsequent obstetric outcomes were studied, until December 2011, to see if the disease recurred. From 450 pregnant women with positive syphilis serology, seen from 1997 to 2004, 166 had at least one more obstetric attendance until December 2011, with 266 new obstetric outcomes. Congenital syphilis (CS) was demonstrated in 81.9% of the initial pregnancies and in 68.4% of the subsequent ones. The main causes of CS in subsequent pregnancies were a negative VDRL that turned positive at delivery, and undocumented treatment. VDRL titers were higher than 1:4 in 50.4% of the initial and 13.3% of the subsequent pregnancies (p < 0.01). Perinatal mortality rate was 119/1000 in initial and 41/1000 in subsequent pregnancies (p < 0.01). CS recurrence was frequent in subsequent pregnancies of women who tested positive for syphilis in a preceding pregnancy. No or inadequate prenatal care was the main risk factor for CS, both in initial and in subsequent pregnancies. These data suggest that non-infected neonates could have been defined as CS cases because of insufficient information about the mother's history.

Entities:  

Mesh:

Year:  2015        PMID: 26331518     DOI: 10.1590/1413-81232015209.20332014

Source DB:  PubMed          Journal:  Cien Saude Colet        ISSN: 1413-8123


  2 in total

Review 1.  Current Perspectives on Prevention of Mother-to-Child Transmission of Syphilis.

Authors:  Eleonor G Lago
Journal:  Cureus       Date:  2016-03-09

2.  Risk factors for syphilis in women: case-control study.

Authors:  Vilma Costa de Macêdo; Pedro Israel Cabral de Lira; Paulo Germano de Frias; Luciana Maria Delgado Romaguera; Silvana de Fátima Ferreira Caires; Ricardo Arraes de Alencar Ximenes
Journal:  Rev Saude Publica       Date:  2017-08-17       Impact factor: 2.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.